X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARC Dialysis, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 08, 2024
Details:
CorMedix intends to use the net proceeds for the commercialization of Taurolock Hep500 (taurolidine), approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Nephrology Product Name: Taurolock Hep500
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: RBC Capital Markets
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Details:
DefenCath is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous catheters (CVCs).
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous catheters (CVCs).
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous catheters (CVCs).
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Defencath is available in Europe and other territories under the brand name Neutrolin. It is used for catheter-related bloodstream infections in patients with end-stage renal disease receiving hemodialysis through a central venous catheter.
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
DefenCath is being developed as a catheter lock solution with an initial indication of use for the reduction of catheter-related bloodstream infections (CRBSIs) in patients with renal failure who are receiving chronic hemodialysis via a central venous catheter.
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
U.S. FDA has accepted for filing the Company’s submitted New Drug Application (NDA) for Defencath™, its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI).
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
The Company plans to use the net proceeds for general corporate purposes, including obtaining regulatory approval and commercialization of Defencath™ in the U.S., research and development, and working capital and capital expenditures.
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SunTrust Robinson Humphrey
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 27, 2020
Details:
Defencath is being developed as a catheter lock solution with an initial indication for use of preventing catheter-related bloodstream infections (CRBSIs) in patients with end-stage renal disease who are receiving hemodialysis via a central venous catheter.
Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
